MET and neoplasm: In a subgroup analysis, we found that miR-122 repression and c-Met induction were distinct in TNM stage II and III tumors (n=25) compared to TNM stage I tumors (n=34) (Figure 7C), consolidating the clinical relevance of miR-122 and c-Met changes with tumor stage progression (i.e., aggressive feature).